Liposome-incorporated Grb2 antisense oligodeoxynucleotide increases the survival of mice bearing bcr-abl-positive leukemia xenografts

International Journal of Oncology

Volumn 31, Issue 5, 2007, Pages 1243-1250

  Tari, Ana M ^a   Gutiérrez Puente, Yolanda ^a,b   Monaco, Giuseppe ^a   Stephens, Clifton ^a   Sun, Tong ^a   Rosenblum, Michael ^a   Belmont, John ^a   Arlinghaus, Ralph ^a   Lopez Berestein, Gabriel ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

Author keywords

Antisense oligodeoxynucleotide; Bcr abl; Grb2

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; BCR ABL PROTEIN; GRB2 PROTEIN, MOUSE; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; LIPOSOME; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; DRUG ANTAGONISM; EXPERIMENTAL LEUKEMIA; GENETICS; INSTITUTE FOR CANCER RESEARCH MOUSE; LEUKOCYTE COUNT; LEWIS RAT; MORTALITY; MOUSE; RAT; TISSUE DISTRIBUTION; XENOGRAFT;

ANIMALS; FUSION PROTEINS, BCR-ABL; GRB2 ADAPTOR PROTEIN; LEUKEMIA, EXPERIMENTAL; LEUKOCYTE COUNT; LIPOSOMES; MICE; MICE, INBRED ICR; NEOPLASM TRANSPLANTATION; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; RATS; RATS, INBRED LEW; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 38449110056     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Buday L and Downward J: Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein and Sos nucleotide exchange factor. Cell 73: 611-620, 1993.
2. Buday L and Downward J: Epidermal growth factor regulates the exchange rate of guanine nucleotides on p21ras in fibroblasts. Mol Cell Biol 13: 1903-1910, 1993.
3. Chardin P, Camonis J, Gale N, et al: Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2. Science 260: 1338-1343, 1993.
4. Gale NW, Kaplan S, Lowenstein EJ, Schlessinger J and Bar-Sagi D: Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras. Nature 363: 88-92, 1993. (Pubitemid 23144969)
5. Downward J: Control of Ras activation. In: Cancer Surveys: Cell Signalling. Parker P and Pawson T (eds). Vol. 27. Cold Spring Harbor Laboratory Press, New York, pp87-100, 1996.
6. Pawson T: Protein modules and signalling networks. Nature 373: 573-580, 1995.
7. Schlessinger J and Ullrich A: Growth factor signaling by receptor tyrosine kinases. Neuron 9: 383-391, 1992.
8. Pendergast A, Quilliam L, Cripe L, et al: BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75: 175-185, 1993.
9. Puil L, Liu J, Gish G, et al: Bcr-Abl oncoproteins bind directly to activators of the ras signalling pathway. EMBO J 13: 764-773, 1994.
10. Lowenstein E, Daly R, Batzer A, et al: The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 70: 431-442, 1992.
11. Xie Y, Pendergast A and Hung M-C: Dominant-negative mutants of Grb2 induced reversal of the transformed phenotypes caused by the point mutation-activated rat HER-2/Neu. J Biol Chem 270: 30717-30724, 1995.
12. Egan S, Giddings B, Brooks M, Buday L, Sizeland A and Weinberg R: Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. Nature 363: 45-51, 1993.
13. Olivier J, Raabe T, Henkemeyer M, et al: A Drosophila SH2- SH3 adaptor protein implicated in coupling the Sevenless tyrosine kinase to an activator of Ras guanine nucleotide exchange, Sos. Cell 73: 179-191, 1993.
14. Simon M, Bowtell D, Dodson G, Laverty T and Rubin G: Ras1 and a putative guanine nucleotide exchange factor perform crucial steps in signaling by the sevenless protein tyrosine kinase. Cell 67: 701-716, 1991.
15. Tortora G, Damiano V, Bianco C, et al: The RIa subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor. Oncogene 14: 923-928, 1997.
16. Wang J, Auger K, Jarvis L, Shi Y and Roberts T: Direct association of Grb2 with the p85 subunit of phosphatidylinositol 3-kinase. J Biol Chem 270: 12774-12780, 1995.
17. Pei Z, Maloney J, Yang L and Williamson JR: A new function for Phospholipase C-γ1: coupling to the adaptor protein GRB2. Arch Biochem Biophys 345: 103-110, 1997.
18. Tari AM: Preparation and application of liposome-incorporated antisense oligonucleotides. Methods Enzymol 313: 372-388, 2000.
19. Tari AM, Arlinghaus R and Lopez-Berestein G: Inhibition of Grb2 and Crkl proteins results in growth inhibition of Philadelphia chromosome positive leukemic cells. Biochem Biophys Res Commun 235: 383-388, 1997.
20. Tari AM, Hung M-C, Li K and Lopez-Berestein G: Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells. Oncogene 18: 1325-1332, 1999.
21. Lim S-J, Lopez-Berestein G, Hung M-C, Lupu R and Tari A: Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells. Oncogene 19: 6271-6276, 2000.
22. Tari AM, Stephens C, Rosenblum M and Lopez-Berestein G: Pharmacokinetics, tissue distribution, and safety of P-ethoxy oligonucleotides incorporated in liposomes. J Liposome Res 8: 251-264, 1998.
23. Gutierrez-Puente Y, Tari AM, Stephens C, Rosenblum M, Reyes T and Lopez-Berestein G: Safety, pharmacokinetics, and tissue distribution of liposomal P-ethoxy antisense oligonucleotides targeted to Bcl-2. J Pharmacol Exp Ther 291: 865-869, 1999.
24. Freireich EJ, Gehan EA, Rall DP, Schmidt LH and Skipper HE: Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50: 219-244, 1966.
25. Lin H, Monaco G, Sun T, et al: Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia. Oncogene 24: 3246-3256, 2005.
26. Dazzi F, Capelli D, Hasserjian R, et al: The kinetics and extent of engraftment of chronic myelogenous leukemia cells in nonobese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology. Blood 92: 1390-1396, 1998.
27. Lewis ID, McDiarmid LA, Samels LM, To LB and Hughes TP: Establishment of a reproducible model of chronic-phase chronic myeloid leukemia in NOD/SCID mice using blood-derived mononuclear or CD34+ cells. Blood 91: 630-640, 1998.
28. Klingmuller U, Wu H, Hsiao J, et al: Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors. Proc Natl Acad Sci USA 94: 3016-3021, 1997.
29. Skorski T, Szczylik C, Ratajczak M, Malaguarnera L, Gewirtz A and Calabretta B: Growth factor-dependent inhibition of normal hematopoiesis by N-ras antisense oligodeoxynucleotides. J Exp Med 175: 743-750, 1992.
30. Cunningham C, Holmlund J, Geary R, et al: A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer 92: 1265-1271, 2001.